User:MathJack13/Brouillon
Stefan Dietmar Anker | |
|---|---|
 | |
| Born | September 19, 1965 |
| Nationality |  Germany |
| Scientific career | |
| Fields | Cardiology, heart failure, muscle wasting, clinical trials |
| Institutions | University medical center, Göttingen , Germany |
| Thesis | MD, PhD, FESC |
Scientific contribution
[edit]Stefan D. Anker, MD, PhD, FESC, is a Professor of Innovative Clinical Trials (W3) at University Medical Center Göttingen in Germany.
The main focus of the Innovative Clinical Trials department is research in the field of chronic heart failure, including the development and clinical testing of new therapies.
He was previously Professor of Cardiology and Cachexia Research (W2) at Charité Berlin between 2002 and 2014.
He studied medicine at Charité medical school Medical School of the Humboldt-University Berlin, Germany, (1987-1993) .
He completed his PhD at the National Heart and Lung Institute of Imperial College London in 1998.
Since then, he has had teaching appointments in several countries (Australia, Italy).
His particular research interests include the pathophysiology and treatment of acute and chronic heart failure, cardiac device therapy,
clinical evaluation of cardiovascular biomarkers, pathophysiology of muscle wasting, cachexia therapy in CHF, ageing, sarcopenia and cancer.
Prof.
Anker is a member and serves on the Boards of several academic organisations. He has authored more than 650 original papers, reviews, and editorials.
Stefan Anker serves on the editorial boards of 5 scientific journals (including European Heart Journal and European Journal of Heart Failure.
He is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle (JCSM, IF 7.88, see www.jcsm.info) and of ESC Heart Failure [1], which is the first open access heart failure journal.
Stefan Anker has won several prizes (including 2 AHA-YIAs), and has obtained a number of fellowships and grants, including 2 NIH grants (WARCEF trial) 2 EU-FP7, 1 IMI grant & 1 Horizon 2020 grant.
Memberships
[edit]Stefan is a member of the German Cardiac Society and of the European Society of Cardiology since 1995.
He is currently Vice President of the European Society of Cardiology (ESC) in charge
of National Cardiac Societies and Communications. He serves in the board of the Heart Failure Association (HFA) of the ESC since 2006.
He was HFA President between 2012 and 2014 and he currently chairs the HFA committee on regulatory affairs.
Stefan Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).
Patents
[edit]| Title | Authors | Date | Link |
|---|---|---|---|
| Method of Treating Cachexia and Sarcopenia | Andrew Justin Stewart Coats; John Beadle; Stefan Dietmar Anker; | 09-Dec-2013 | http://www.google.com/patents/US20140194484 |
| Method for enhancing the performance and general condition of a subject | Stefan Dietmar Anker; | 29-Apr-2013 | http://www.google.com/patents/US8655445 |
| Prevention and treatment of sarcopenia | Jochen Springer; Stefan Dietmar Anker; Andrew Justin Stewart Coats; John Beadle; | 29-Apr-2010 | http://www.google.com/patents/US8835485 |
Publications
[edit]| Title | Authors | Citation | Date | Link |
|---|---|---|---|---|
| Central Chemoreceptor Sensitivity Is Not Enhanced in Contemporary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment. | Bartłomiej Paleczny; Martyna Olesinska; Agnieszka E Siennicka; Piotr Niewiński; Ewa Anita Jankowska; Beata Ponikowska; Waldemar Banasiak; Stephan VON Haehling; Stefan Dietmar Anker; Piotr P Ponikowski; | Paleczny B, et al. Journal of cardiac failure. 2017 Jan;23(1):83-87 | 01-Jan-2017 | http://dx.doi.org/10.1016/j.cardfail.2016.11.003 |
| Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). | Masaaki Konishi; Nicole Ebner; Jochen Springer; Joerg Christian Schefold; Wolfram Doehner; Thomas Bernd Dschietzig; Stefan Dietmar Anker; Stephan von Haehling; | Konishi M, et al. Circulation journal : official journal of the Japanese Circulation Society. 2016 Dec 22;81(1):52-61 | 22-Dec-2016 | http://dx.doi.org/10.1253/circj.CJ-16-0791 |
| Neuromuscular electrical stimulation for muscle wasting in heart failure patients. | Masakazu Saitoh; Marcelo Rodrigues dos Santos; Markus S Anker; Stefan Dietmar Anker; Stephan von Haehling; Jochen Springer; | Saitoh M, et al. International journal of cardiology. 2016 Dec 15;225:200-205 | 15-Dec-2016 | http://dx.doi.org/10.1016/j.ijcard.2016.09.127 |
Clinical Trials
[edit]| Title | Authors | Date | Link |
|---|---|---|---|
| The remedē® System for the Treatment of Central Sleep Apnea in Daily Practice (TREAT-CSA) | Stefan Dietmar Anker; Christoph Stellbrink; | 25-Sep-2015 | http://clinicaltrials.gov/ct2/show/NCT02577445 |
| Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) | Rostislav S Karpov; Piotr Rozentryt; Eugeniy V Shlyakhto; Vsevolod A Tkachuk; John George Franklin Cleland; Giuseppe Massimo Claudio Rosano; Jens Friedrich Jordan; Stephan von Haehling; Yelena V Parfyonova; Stefan Dietmar Anker; Piotr P Ponikowski; Mitja | 17-May-2013 | http://clinicaltrials.gov/ct2/show/NCT01872299 |
| Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI) (STRAWINSKI) | Stefan Dietmar Anker; Andreas P. Meisel; | 21-Dec-2010 | http://clinicaltrials.gov/ct2/show/NCT01264549 |
| Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients | Stefan Dietmar Anker; | 13-Feb-2009 | http://clinicaltrials.gov/ct2/show/NCT00852020 |
| Biomarkers in Acute Heart Failure (BACH) | Alan S. Maisel; Frank W Peacock; Stefan Dietmar Anker; | 28-Sep-2007 | http://clinicaltrials.gov/ct2/show/NCT00537628 |